Insights

iPSC expertise Ncardia specializes in human iPSC technology for drug discovery and disease modeling, offering co-developed, tailored iPSC-based solutions. Sales opportunities exist in partnering with pharma and biotech companies seeking scalable stem cell models and high-throughput screening capabilities.

Cross-species models Recent launch of Ncyte NHP-C vCardiomyocytes provides ventricular-like cardiomyocytes from cynomolgus monkey iPSCs for scalable, ethical cross-species cardiac studies. This positions Ncardia to engage customers requiring cross-species validation and translational models.

Cellistic collaboration Strategic collaboration with Cellistic to enable large-scale iPSC-derived cell therapy process development and manufacturing signals a capability to support regenerative medicine programs and allogeneic cell therapy pipelines.

Ready-to-use assays The panel of ready-to-use assays introduced in 2024 accelerates screening and decision-making for therapeutic candidates, offering a near-term value proposition for customers needing efficient data generation and disease-relevant readouts.

Global reach & growth With a global presence across Europe and North America, ongoing leadership hires and a growing portfolio of platforms and services suggest expanding sales opportunities in multinational collaborations, sponsored projects, and large-scale research programs.

Similar companies to Ncardia

Ncardia Tech Stack

Ncardia uses 8 technology products and services including AdRoll, HubSpot Content Hub, Salesforce, and more. Explore Ncardia's tech stack below.

Media & News

Ncardia's Email Address Formats

Ncardia uses at least 4 email formats:
Ncardia Email FormatsExamplePercentage
First.Last@ncardia.comJohn.Doe@ncardia.com
89%
First.MiddleLast@ncardia.comJohn.MichaelDoe@ncardia.com
8%
FirLast@ncardia.comJohDoe@ncardia.com
2%
First@ncardia.comJohn@ncardia.com
1%

Frequently Asked Questions

What is Ncardia's official website and social media links?

Minus sign iconPlus sign icon
Ncardia's official website is ncardia.com and has social profiles on LinkedIn.

How much revenue does Ncardia generate?

Minus sign iconPlus sign icon
As of October 2026, Ncardia's annual revenue is estimated to be $1M - $10M.

What is Ncardia's SIC code and NAICS code?

Minus sign iconPlus sign icon
Ncardia's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Ncardia have currently?

Minus sign iconPlus sign icon
As of October 2026, Ncardia has approximately 42 employees across 2 continents, including Europe and North America. Key team members include COO: B. D. F., CSO: H. B. and Chief People Officer: V. D. Explore Ncardia's employee directory with LeadIQ.

What industry does Ncardia belong to?

Minus sign iconPlus sign icon
Ncardia operates in the Biotechnology Research industry.

What technology does Ncardia use?

Minus sign iconPlus sign icon
Ncardia's tech stack includes AdRoll, HubSpot Content Hub, Salesforce, Shopify, Microsoft 365, Box, Microsoft Teams and Piwik PRO Core.

What is Ncardia's email format?

Minus sign iconPlus sign icon
Ncardia's email format typically follows the pattern of First.Last@ncardia.com. Find more Ncardia email formats with LeadIQ.

When was Ncardia founded?

Minus sign iconPlus sign icon
Ncardia was founded in 2011.
Ncardia logo

Ncardia

Biotechnology ResearchSouth Holland, Netherlands11-50 Employees

Ncardia is a biotechnology company based in Leiden, Netherlands, specializing in drug discovery and human induced pluripotent stem cell (iPSC) technology. It operates across Europe and North America, collaborating with biopharmaceutical companies to apply stem cell-derived models at any development stage and across multiple modalities. The company has built expertise to differentiate, manufacture, and characterize iPSC-derived cells and disease models, enabling disease modeling and high-throughput screening to support drug discovery. It emphasizes listening to customer plans and co-developing iPSC-based solutions tailored to specific project requirements. A notable recent development is the 2025 launch of Ncyte NHP-C vCardiomyocytes, the first commercially available ventricular-like cardiomyocytes derived from iPSCs of cynomolgus monkeys.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2011
Employees
11-50

Section iconFunding & Financials

  • $1M - $10M

    Ncardia's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.